You are here » Home » Companies » Company Overview » Ami Organics Ltd

Ami Organics Ltd.

BSE: 543349 Sector: Health care
NSE: AMIORG ISIN Code: INE00FF01017
BSE 00:00 | 28 Oct 1052.45 -58.55
(-5.27%)
OPEN

1119.95

HIGH

1119.95

LOW

1040.00

NSE 00:00 | 28 Oct 1051.05 -61.70
(-5.54%)
OPEN

1112.00

HIGH

1115.45

LOW

1041.10

OPEN 1119.95
PREVIOUS CLOSE 1111.00
VOLUME 15483
52-Week high 1438.50
52-Week low 841.20
P/E 70.07
Mkt Cap.(Rs cr) 3,835
Buy Price 0.00
Buy Qty 0.00
Sell Price 0.00
Sell Qty 0.00
OPEN 1119.95
CLOSE 1111.00
VOLUME 15483
52-Week high 1438.50
52-Week low 841.20
P/E 70.07
Mkt Cap.(Rs cr) 3,835
Buy Price 0.00
Buy Qty 0.00
Sell Price 0.00
Sell Qty 0.00

Ami Organics Ltd. (AMIORG) - Company History

The Company was initially formed as a partnership firm in the name of Ami Organics with effect from 03 January 2004 at Surat India. The firm converted into a private limited company under the Companies Act 1956 under the name of Ami Organics Private Limited with a certificate of incorporation dated 12 June 2007. Subsequently the Company was converted into a public limited company following which the Company's name was changed to Ami Organics Limited and a fresh certificate of incorporation was issued by RoC on 18 April 2018. The company is one of the leading research and development (R&D) driven manufacturers of specialty chemicals with varied end usage focussed towards the development and manufacturing of advanced pharmaceutical intermediates for regulated and generic active pharmaceutical ingredients (APIs) and New Chemical Entities (NCE) and key starting material for agrochemical and fine chemicals especially from the recent acquisition of the business of Gujarat Organics Limited (GOL). As per the F&S Report the company is one of the major manufacturers of Pharma Intermediates for certain key APIs including Dolutegravir Trazodone Entacapone Nintedanib and Rivaroxaban. The Pharma Intermediates which the company manufacture find application in certain high-growth therapeutic areas including anti-retroviral antiinflammatory anti-psychotic anti-cancer anti-Parkinson anti-depressant and anti-coagulant commanding significant market share both in India and globally. The company's Pharma Intermediates used for manufacturing of APIs and NCEs portfolio has expanded from over 425 products as of 31 March 2019 to over 450 products as of 31 March 2021.During the FY2021 Bonus shares were issued to the existing shareholders of the Company as on the record date of 31.03.2021 by issue of 21000000 Equity shares of face value of Rs. 10 each.The Bonus shares were allotted in the ratio of 2:1 i.e Two new equity shares for every one existing shares of the company.As on 31 March 2021the company has one joint venture companynamely AMI Onco-TheranosticsLLC.During the month of September 2021the company came out with an IPO which comprised a fresh issue of Rs 200 crore and an offer for sale of Rs 370 crore by shareholdersmopped up a total of Rs 570 crore through its public issue.The company will utilise the proceeds from fresh issue and pre-IPO placement for repaying debts and meeting working capital requirements.The allotted shares were listed on the BSE Ltd and National Stock Exchange of India(NSE) on 14 September 2021.

.